KR100642184B1 - 아릴술폰아닐리드 우레아 - Google Patents

아릴술폰아닐리드 우레아 Download PDF

Info

Publication number
KR100642184B1
KR100642184B1 KR1020017003646A KR20017003646A KR100642184B1 KR 100642184 B1 KR100642184 B1 KR 100642184B1 KR 1020017003646 A KR1020017003646 A KR 1020017003646A KR 20017003646 A KR20017003646 A KR 20017003646A KR 100642184 B1 KR100642184 B1 KR 100642184B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
pharmaceutical composition
pharmaceutically acceptable
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017003646A
Other languages
English (en)
Korean (ko)
Other versions
KR20010079892A (ko
Inventor
조나탄 비. 휴즈
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크 filed Critical 암젠 인크
Publication of KR20010079892A publication Critical patent/KR20010079892A/ko
Application granted granted Critical
Publication of KR100642184B1 publication Critical patent/KR100642184B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
KR1020017003646A 1998-09-23 1999-09-21 아릴술폰아닐리드 우레아 Expired - Fee Related KR100642184B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10088898P 1998-09-23 1998-09-23
US60/100,888 1998-09-23

Publications (2)

Publication Number Publication Date
KR20010079892A KR20010079892A (ko) 2001-08-22
KR100642184B1 true KR100642184B1 (ko) 2006-11-10

Family

ID=22282047

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017003646A Expired - Fee Related KR100642184B1 (ko) 1998-09-23 1999-09-21 아릴술폰아닐리드 우레아

Country Status (23)

Country Link
US (3) US6214880B1 (https=)
EP (1) EP1115701B1 (https=)
JP (1) JP3926983B2 (https=)
KR (1) KR100642184B1 (https=)
CN (1) CN100335461C (https=)
AT (1) ATE240940T1 (https=)
AU (1) AU747663B2 (https=)
BR (1) BR9913903A (https=)
CA (1) CA2343204C (https=)
CZ (1) CZ2001934A3 (https=)
DE (1) DE69908156T2 (https=)
DK (1) DK1115701T3 (https=)
EA (1) EA003924B1 (https=)
ES (1) ES2194547T3 (https=)
HU (1) HUP0103884A3 (https=)
IL (2) IL142066A0 (https=)
NO (1) NO20011453L (https=)
NZ (1) NZ510435A (https=)
PL (1) PL198394B1 (https=)
PT (1) PT1115701E (https=)
SK (1) SK284757B6 (https=)
WO (1) WO2000017159A1 (https=)
ZA (1) ZA200102033B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508644D0 (en) * 1995-04-28 1995-06-14 Exxon Chemical Patents Inc Fuel compositions
ES2194547T3 (es) * 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU775305B2 (en) * 1999-07-29 2004-07-29 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
US6664259B2 (en) 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
AR031098A1 (es) * 2000-03-16 2003-09-10 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2002306604B2 (en) 2001-02-28 2007-09-13 Onconova Therapeutics, Inc. N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
JP4434744B2 (ja) * 2002-01-30 2010-03-17 アムジェン インコーポレイテッド アリールスルホンアミドベンジル化合物
US7112606B2 (en) * 2002-01-30 2006-09-26 Amgen Inc. Heterocyclic arylsulfonamidobenzylic compounds
EP1534284B1 (en) 2002-02-28 2011-07-27 Temple University - Of The Commonwealth System of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
EP1660459A2 (en) * 2003-08-12 2006-05-31 Amgen inc. Arylsulfonamidobenzylic compounds
US20050124664A1 (en) * 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050154455A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
US20060062822A1 (en) * 2004-09-21 2006-03-23 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20070027530A1 (en) * 2005-07-26 2007-02-01 Medtronic Vascular, Inc. Intraluminal device, catheter assembly, and method of use thereof
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070067020A1 (en) * 2005-09-22 2007-03-22 Medtronic Vasular, Inc. Intraluminal stent, delivery system, and a method of treating a vascular condition
AR060562A1 (es) * 2006-04-21 2008-06-25 Smithkline Beecham Corp Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas.
US8097626B2 (en) * 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
AR061571A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
WO2009088549A2 (en) * 2007-10-19 2009-07-16 The Board Of Regents Of The University Of Texas System Methods of inhibiting bacterial virulence and compounds relating thereto
EP2385831A4 (en) * 2009-01-09 2014-03-26 Uab Research Foundation SMALL MOLECULAR HEMMER OF NADS, NAMNAT AND NMNAT
US9444712B2 (en) 2012-11-21 2016-09-13 Cisco Technology, Inc. Bandwidth on-demand services in multiple layer networks
CN104797429B (zh) * 2012-11-21 2017-04-19 日本曹达株式会社 使用非酚类化合物的记录材料、记录片和将非酚类化合物用于显色剂的方法
JPWO2017170826A1 (ja) * 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−１受容体作用増強活性を有する化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1955207A (en) 1931-09-16 1934-04-17 Ig Farbenindustrie Ag Mothproofing agent
DE622494C (de) 1932-01-03 1935-11-29 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Mono- bzw. Polynitropolysulfonen und deren Reduktionsprodukten
US2358365A (en) 1940-08-03 1944-09-19 Parke Davis & Co Sulphonamide derivatives and process for obtaining the same
US2402623A (en) 1943-06-24 1946-06-25 Rohm & Haas Nu-nitroaryl haloarylsulphonamides
CH362688A (de) 1957-09-10 1962-06-30 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
GB938890A (en) 1961-02-03 1963-10-09 Boots Pure Drug Co Ltd New fungicidal compositions and compounds
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
GB1242057A (en) 1968-07-04 1971-08-11 Ici Ltd Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (nl) 1970-04-13 1984-07-16 Minnesota Mining & Mfg Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking.
FR2456731A1 (fr) 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
DE3623184A1 (de) 1986-07-10 1988-01-14 Kali Chemie Ag Verfahren zur herstellung von n-fluorsulfonamiden
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
FR2645537B1 (fr) 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5189211A (en) 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
DE69724777T2 (de) * 1996-02-22 2004-07-15 Tularik, Inc., South San Francisco Pentafluorobenzensulfonamiden und analoge
PT939627E (pt) * 1996-07-19 2004-02-27 Tularik Inc Pentafluorobenzenossulfonamidas e analogos
WO1999024407A1 (en) 1997-11-10 1999-05-20 Array Biopharma, Inc. Compounds which inhibit tryptase activity
ATE282591T1 (de) 1997-12-23 2004-12-15 Warner Lambert Co Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
ES2194547T3 (es) * 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
AU775305B2 (en) * 1999-07-29 2004-07-29 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound

Also Published As

Publication number Publication date
IL142066A0 (en) 2002-03-10
ATE240940T1 (de) 2003-06-15
PT1115701E (pt) 2003-09-30
HUP0103884A3 (en) 2002-11-28
US20030207864A1 (en) 2003-11-06
ZA200102033B (en) 2001-09-12
DE69908156D1 (de) 2003-06-26
DK1115701T3 (da) 2003-06-23
NO20011453L (no) 2001-05-23
AU6058099A (en) 2000-04-10
AU747663B2 (en) 2002-05-16
EA003924B1 (ru) 2003-10-30
EP1115701A1 (en) 2001-07-18
KR20010079892A (ko) 2001-08-22
IL142066A (en) 2006-07-05
CN100335461C (zh) 2007-09-05
SK284757B6 (sk) 2005-11-03
PL346797A1 (en) 2002-02-25
SK4002001A3 (en) 2001-09-11
US6214880B1 (en) 2001-04-10
HK1038913A1 (en) 2002-04-04
HUP0103884A2 (hu) 2002-05-29
DE69908156T2 (de) 2003-12-24
BR9913903A (pt) 2001-07-03
WO2000017159A1 (en) 2000-03-30
EP1115701B1 (en) 2003-05-21
US7060718B2 (en) 2006-06-13
US20010027211A1 (en) 2001-10-04
CN1319088A (zh) 2001-10-24
ES2194547T3 (es) 2003-11-16
CZ2001934A3 (cs) 2001-08-15
EA200100376A1 (ru) 2001-08-27
US6583165B2 (en) 2003-06-24
NO20011453D0 (no) 2001-03-22
CA2343204C (en) 2008-04-29
JP3926983B2 (ja) 2007-06-06
JP2002526472A (ja) 2002-08-20
NZ510435A (en) 2003-04-29
CA2343204A1 (en) 2000-03-30
PL198394B1 (pl) 2008-06-30

Similar Documents

Publication Publication Date Title
KR100642184B1 (ko) 아릴술폰아닐리드 우레아
EP3565815B1 (en) Compounds as bcl-2-selective apoptosis-inducing agents
CN101778563B (zh) 调节细胞凋亡的组合物和方法
CA2048172C (fr) Sulfonamides substitues, procedes de preparation et medicaments les contenant
CA2889389C (en) Benzene sulfonamide thiazole compounds
KR20010101675A (ko) 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
EP1951663B1 (en) (r)-arylkylamino derivatives and pharmaceutical compositions containing them
CA3167361A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CA2286186A1 (en) Activated iododerivatives for the treatment of cancer and aids
JP6927959B2 (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
KR101941794B1 (ko) 아미노설포닐계 화합물, 이의 제조 방법 및 용도
JPH05345756A (ja) スルホンイミドアミド類
US20080070946A1 (en) Hydroxymethylbenzothiazoles Amides
EP1285911A2 (en) Arylsulfonanilide ureas
HK1038913B (en) Arylsulfonanilide ureas
CN106957298B (zh) 一种硫辛酸苯酚酯衍生物及其制备方法和应用
MXPA01002717A (es) Ureas de arilsulfonanilida
CN109796418B (zh) 含有4-苯基-1,2,3-三氮唑的苯丙氨酸衍生物及其制备方法与应用
JPH05294923A (ja) 抗腫瘍組成物および治療法
KR101255566B1 (ko) 세포증식 억제제로서 유용한 ｎ５-(피리미딘-4-일)―１ｈ－인다졸―３，５―디아민 유도체，이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 그 제조방법
JP2008208086A (ja) ３−アミノ−２−インドリルブチロラクタム誘導体、その製造法、及びこれを有効成分とする医薬
WO2001012593A1 (en) Arylsulfonanilide derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091028

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091028